passive antibody therapy passive antibody therapy passive antibody therapy, also called serum therapy, is a subtype of passive immunotherapy that administers antibodies (same as immunoglobin) to target and kill pathogens or cancer cells. it is designed to draw support from foreign antibodies that are donated from a person, extracted from animals, or made in the laboratory to elicit an immune response instead of relying on the innate immune system to fight disease. it has a long history from the 18th century for treating infectious diseases and is now a common cancer treatment. the mechanism of actions include: antagonistic and agonistic reaction, complement-dependent cytotoxicity (cdc), and antibody-dependent cellular cytotoxicity (adcc). history the timeline of the development of passive antibody therapy. the prevalence roused in the early 1900s and withdrew in the 1930s. it was revived in 1975 and became common cancer therapeutic. passive antibody therapy was first propounded by emil von behring and shibasaburo kitasato in 1890 to treat diphtheria after the observation of immunization in rabbits after injecting serum from tetanus-immunized rabbits. later in 1891, paul ehrlich joined behring's and kitasato's research to ameliorate immunizability from lethal toxins. this established the basis of antibody immunotherapy. with the ideology of using antibody serum to treat infectious diseases, the three scientists standardized serum production in dairy cows and merchandised serum vaccines for tetanus and diphtheria. the prevalence of serum therapy surged in the early 19th century. when the h1n1 influenza pandemic (spanish flu) struck the us and europe, serum containing antibodies from recovered patients are prevalently injected into patients. with proven therapeutic effects, the applications expanded to other viral and bacterial infections, such as pneumococcus, meningococcus, and rabies, despite an unknown underlying mechanism. yet, severe anaphylactic reactions and hypersensitivity were common, ergo, serum therapy was pulled out from the market in the 1940s. the resurrection of antibody immunotherapy contributed to cesar milstein and georges j. f. kohler, who manifested the mass production of pure monoclonal antibodies with limited adverse effects in 1975. since then, passive antibody therapy has become prevailed as cancer therapeutics and viral treatments. classification of passive immunity therapy monoclonal antibodies (mab) polyclonal antibodies (pab) characteristics a single type of antibodies that recognize one epitope of an antigen contain a mixture of antibodies that can recognize multiple epitopes on a single type of antigen manufacture process create hybridoma: isolate b lymphocytes from animal spleen and fuse with myeloma cell line directly collect serum from immunized animals and purify the solution to remove other serum proteins advantages - high homogeneity (low batch-to-batch variability) - high specificity and low cross-reactivity - high sensitivity - inexpensive to produce - high overall affinity - bind to target antigen quicker disadvantages - expensive to produce - long production time - overall affinity is lower than polyclonal antibodies - high batch-to-batch variability - low specificity and high cross-reactivity monoclonal antibodies (mab) a general representation of the production of monoclonal antibodies. monoclonal antibodies are manufactured ex vivo from a single b lymphocyte. serum from immunized animals or humans is first extracted and purified to collect b lymphocytes from the spleen, which are then fused with plasma cell myeloma. after culturing the fused myeloma cell lines, the colonies are selected with the antigens: positive colonies with suitable antibodies can bind to the epitope of the antigen and kill pathogens, whereas colonies without targeted antibodies are eliminated. upon injection, these homogenous antibodies produced from a single b cell can target a specific epitope on the antigen. the major advantage of using monoclonal antibodies is their specific action towards the target since it only contains one antibody binding site per se, it minimizes cross-reactivity (the activity that antibodies unintentionally bind to non-targeted antigens). however, monoclonal antibodies also mean that overall affinity is lower owing to the limited ability to recognize different epitopes on the antigens, which may lead to incomplete elimination of pathogens and tumor cells. the production time and cost is high as well, limiting its generalizability and prevalence of usage. polyclonal antibodies (pab) the process of manufacturing polyclonal antibodies is similar to that of monoclonal antibodies, which begins with inoculation of antigen conjugate into suitable animals, except multiple b lymphocytes are collected and cultured instead of a single b lymphocyte. production of polyclonal antibodies circumvents the procedure of ex vivo fabrication of hybridoma cell line and requires minimal purification. the manufacturing cost and time are wherefore reduced. due to a heterogeneous origin, the antibodies express various subtypes of immunoglobulin against the antigen which has an overall higher affinity and can better detect low-quantity antigens by targeting different epitopes on the antigen. however, it also provokes an increased chance of non-specific reactivity because the antibodies might bind to non-diseases causing substances. in addition, as serum batch may contain various antibodies at different concentrations, it is laborious to corroborate the constituents of every batch. mechanism of action since some patients fail to produce antibodies effectively and hence have poorer immune responses, passive antibody therapy can reinforce their immune system through the introduction of antibodies from donors. antibodies are glycoproteins that are naturally produced by the immune system. each antibody contains four polypeptides of y shapes and has unique recognition sites of the targets, such as cell surface antigen, and transmembrane proteins on cancer cells and infectious organisms (viruses and bacteria). upon binding to the antigen, antibodies trigger different cascades to neutralize toxins and kill the cells. there are three ways of action: antagonistic and agonistic reaction, complement-dependent cytotoxicity (cdc), and antibody-dependent cellular cytotoxicity (adcc). antagonistic reaction (neutralization) and agonistic reaction antagonism by antibodies eliminates antigens by binding to the relevant fc receptors or pathogens for disrupting the toxins from binding to the receptors. in cancers, tumor cells escape immune vigilance by binding to checkpoint proteins on immune cells for inhibiting immune signaling and downregulating the expression of major histocompatibility class i (mhc i). antagonistic antibodies, also called immune checkpoints inhibitors, obstruct the binding between cancer cells and immune checkpoints to antagonize cancer cells’ action and restore immune surveillance. therefore, immune cells can recognize the surface antigens on the tumor cells to elicit immune responses. examples of drugs that exploit such a mechanism include pembrolizumab and telimomab. apart from directing the inhibitory pathways, agonistic antibodies can target immunostimulatory receptors to elicit immune responses. upon binding between cluster of differentiation proteins (cd proteins) and agonistic antibodies, antigen-presenting cells, such as dendritic cells, b lymphocytes and monocytes, are stimulated to secrete proinflammatory cytokines to remove pathogens and malignant cells. for example, the ligation of cd40 monoclonal antibodies and cd40 on tumor cells license antigen-presenting cells (predominantly dendritic cells) to increase the presentation of tumor-associated antigens (taa) to local cytotoxic t lymphocytes to kill tumor cells. illustration of complement cascade complement-dependent cytotoxicity (cdc) pathway antibodies can also trigger the classical pathway – one of the three pathways of the complement cascade. briefly, the c1 protein attaches to the pathogen surface and the antibody-antigen complex that culminates in the generation of c3 convertase, followed by the cleavage of c3 protein into c3a and c3b protein. c3a protein serves as an inflammation mediator to recruit phagocytes. on the other hand, c3 protein can opsonize pathogens and bind to c3 convertase to catalyze the formation of c5 convertase to produce c5a and c5b for terminal complement components assembly. the formation of complement proteins (c3a, c3b, c5a, c5b, etc.) ultimately congregates into a membrane-attack complex to lyse the membrane of pathogens. in addition to the generation of complement proteins, c1 complex also induces the activation of b cells, monocytes, macrophages, and neutrophils to trigger immune responses, for instance, vasodilation and increased vascular permeability at the infection site. antibody-dependent cellular cytotoxicity (adcc) pathway several monoclonal antibody drugs such as rituximab manipulate the adcc pathway to eradicate cancer cells. firstly, the fab region of the antibodies (tip of the y shaped-antibody) first binds to the epitope of the pathogens or the immunoreceptors of cancer cells; whereas the fc region (stem of the antibody) binds to natural killer cells to phosphorylate the immunoreceptor. several notable immunoreceptors for cancer treatment include epidermal growth factor receptor (efgr), insulin-like growth factor receptor (igfr), and cmet as they are commonly overexpressed in malignant cells. phosphorylation of immunoreceptors triggers the release of cytotoxic granules from the natural killer cells which sequentially perturbs cell-cell signaling via the induction of the apoptotic cascade (bax, bad, etc.), leading to cell death and enhancing the susceptibility of cancer cells to chemotherapy or radiotherapy. application on cancer the structure of monoclonal antibodies. mouse (top-left, o), chimeric (top-right, xi), humanized (bottom-left, zu), and fully human(bottom right, u) antibodies. human parts are shown in brown, and murine parts in blue. rituximab binds to cd20 on a b cell surface. brentuximab vedotin is an antibody-drug conjugate.passive antibody administration has become a widely approved cancer treatment following the development of monoclonal antibody (mab). since these antibodies originated from mice, they were wrought with problems of immunogenetics and poor abilities to induce an immune response in the human body, limiting their clinical applicability. later development of antibody engineering enabled the production of chimeric antibodies (antibodies with human fc region and mouse fab region), humanized antibodies (antibodies with replaced mouse complementarity-determining regions and human backbone), and full human antibodies (antibodies produced by transgenic mice), which satisfactorily addressed many of these problems and were suitable for the clinical cancer treatment. cetuximab cetuximab (trade name: erbitux ) is a recombinant chimeric monoclonal antibody designed to treat metastatic colorectal cancer and head and neck cancer. in numerous cancers, the epidermal growth factor receptor (egfr) is often inappropriately activated and overexpressed in cancer cells, leading to uncontrolled cell growth. cetuximab blocks ligand binding of egfr and inhibits intracellular downstream events critical for tumor survival, thereby inducing tumor regression by reducing cell proliferation and increasing apoptosis. it is administered by intravenous injection and is often prescribed in combination with radiotherapy or other chemotherapeutic regimens such as irinotecan. since egfr plays an essential role in maintaining skin integrity, one serious side effect of cetuximab therapy is skin problems such as acne-like rash, skin drying and cracking due to the inhibition of egfr. other serious side effects are severe allergic reactions and heart attacks. rituximab in 1997, the fda approved rituximab (trade names: rituxan, mabthera) as the first monoclonal antibody for clinical cancer treatment. this drug directly targets cd20 that is found on the surface of both normal and malignant b cells and is indicated to treat blood cancers, such as non-hodgkin's lymphoma (a type of b cell lymphoma) and chronic lymphocytic leukemia (b cell malignancy), and other conditions like rheumatoid arthritis and vasculitis. the mechanism of action includes b-cell lysis by antibody-dependent cellular cytotoxicity (adcc), and complement-dependent cytotoxicity (cdc). common side effects include itching, headache, nausea, diarrhea and low blood pressure. brentuximab vedotin brentuximab vedotin (trade name: adcetris) is a cd30 targeted antibody-drug conjugate (adc), i.e. a monoclonal antibody chemically linked to a drug, and is constructed by chimeric anit-cd30 igg1 antibody (cac10), monomethyl auristatin e (mmae, a potent cytotoxic drug) and a linker that attaches mmae covalently to cac10. the binding of brentuximab vedotin to tumor cells is followed by the release of cytotoxic drug mmae, which destroys the microtubule network within the cell and induces cell apoptosis. brentuximab vedotin became the first antibody-drug conjugate approved by fda to treat hodgkin's lymphoma and anaplastic large-cell lymphoma in 2011. application on infectious diseases palivizumab in 1998, the fda approved the medical use of palivizumab (trade name: synagis), which is a humanized monoclonal antibody used as prophylaxis to prevent severe diseases caused by respiratory syncytial virus (rsv) - the leading cause of lower respiratory tract infections in infants. the drug is recommended for infants with a high risk of rsv infection due to prematurity or diseases such as congenital heart disease (chd) and bronchopulmonary dysplasia (bpd). however, it will not treat children already infected with rsv. injected intramuscularly, it binds to rsv fusion proteins to prevent rsv from binding to host cell receptors and uptake. common side effects are diarrhea, vomiting, runny nose and other cold symptoms. an overview of hiv entry. ibalizumab is used to prevent the binding of hiv to cd4 and thus blocks hiv entry. ibalizumab ibalizumab (trade name: trogarzo) is a new antiviral drug specifically for adults with hiv who have tried but developed resistant against other hiv